Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge | 07.01.2019

Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:  Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement to Elasmogen’s proprietary NDure half-life extension technology for use in two non-disclosed targets.  ImmunoForge will be responsible […]